Robinson Value Management Ltd. acquired a new stake in shares of Amgen Inc. (NASDAQ:AMGN) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 5,150 shares of the medical research company’s stock, valued at approximately $753,000.

Several other hedge funds have also recently added to or reduced their stakes in AMGN. Morgan Stanley increased its stake in Amgen by 8.0% in the third quarter. Morgan Stanley now owns 8,678,786 shares of the medical research company’s stock valued at $1,447,708,000 after buying an additional 639,410 shares during the last quarter. Numeric Investors LLC increased its stake in Amgen by 58.2% in the second quarter. Numeric Investors LLC now owns 1,620,496 shares of the medical research company’s stock valued at $246,558,000 after buying an additional 596,160 shares during the last quarter. Old Mutual Global Investors UK Ltd. increased its stake in Amgen by 172.8% in the third quarter. Old Mutual Global Investors UK Ltd. now owns 812,391 shares of the medical research company’s stock valued at $135,514,000 after buying an additional 514,557 shares during the last quarter. Bahl & Gaynor Inc. increased its stake in Amgen by 106.6% in the third quarter. Bahl & Gaynor Inc. now owns 818,393 shares of the medical research company’s stock valued at $136,516,000 after buying an additional 422,246 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale increased its stake in Amgen by 69.7% in the third quarter. DekaBank Deutsche Girozentrale now owns 907,738 shares of the medical research company’s stock valued at $150,255,000 after buying an additional 372,883 shares during the last quarter. Hedge funds and other institutional investors own 79.04% of the company’s stock.

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Shares of Amgen Inc. (NASDAQ:AMGN) opened at 172.11 on Friday. The stock has a market cap of $127.02 billion, a price-to-earnings ratio of 16.81 and a beta of 1.15. The company has a 50-day moving average price of $158.68 and a 200-day moving average price of $159.34. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $176.85.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, February 2nd. The medical research company reported $2.89 EPS for the quarter, beating analysts’ consensus estimates of $2.79 by $0.10. Amgen had a return on equity of 29.42% and a net margin of 33.59%. The company earned $5.97 billion during the quarter, compared to analysts’ expectations of $5.75 billion. During the same period last year, the business posted $2.61 EPS. Amgen’s revenue for the quarter was up 7.7% on a year-over-year basis. On average, analysts expect that Amgen Inc. will post $12.34 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 8th. Investors of record on Wednesday, February 15th will be issued a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a yield of 2.67%. This is a boost from Amgen’s previous quarterly dividend of $1.00. The ex-dividend date of this dividend is Monday, February 13th. Amgen’s dividend payout ratio (DPR) is 44.92%.

“Robinson Value Management Ltd. Takes Position in Amgen Inc. (AMGN)” was originally published by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The legal version of this piece of content can be accessed at http://www.dailypolitical.com/2017/02/17/robinson-value-management-ltd-takes-position-in-amgen-inc-amgn.html.

Several analysts recently weighed in on AMGN shares. RBC Capital Markets set a $190.00 price objective on Amgen and gave the company a “buy” rating in a report on Wednesday, January 4th. Zacks Investment Research downgraded Amgen from a “hold” rating to a “sell” rating in a report on Tuesday, January 3rd. Vetr upgraded Amgen from a “buy” rating to a “strong-buy” rating and set a $182.34 price objective for the company in a report on Monday, October 24th. Leerink Swann reiterated a “market perform” rating and issued a $163.00 target price (down from $193.00) on shares of Amgen in a report on Friday, October 28th. Finally, Bank of America Corporation upgraded shares of Amgen from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $156.68 to $192.00 in a report on Wednesday, February 1st. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and fourteen have given a buy rating to the company. Amgen currently has an average rating of “Hold” and an average target price of $181.90.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).

5 Day Chart for NASDAQ:AMGN

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.